Current Indications for Growth Hormone Therapy for Children and Adolescents
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Growth hormone (GH) therapy has been appropriate for severely GH-deficient children and adolescents since the 1960s. Use for other conditions for which short stature was a component could not be seriously considered because of the small supply of human pituitary-derived hormone. That state changed remarkably in the mid-1980s because of Creutzfeldt-Jakob disease associated with human pituitary tissue-derived hGH and the development of a (nearly) unlimited supply of recombinant, 22 kDa (r)hGH. The latter permitted all GH-deficient children to have access to treatment and one could design trials using rhGH to increase adult height in infants, children and adolescents with causes of short stature other than GH deficiency, as well as trials in adult GH-deficient men and women. Approved indications (US Food and Drug Administration) include: GH deficiency, chronic kidney disease, Turner syndrome, small-for-gestational age with failure to catch up to the normal height percentiles, Prader-Willi syndrome, idiopathic short stature, SHOX gene haploinsufficiency and Noonan syndrome (current to October 2008). The most common efficacy outcome in children is an increase in height velocity, although rhGH may prevent hypoglycemia in some infants with congenital hypopituitarism and increase the lean/fat ratio in most children - especially those with severe GH deficiency or Prader-Willi syndrome. Doses for adults, which affect body composition and health-related quality of life, are much lower than those for children, per kilogram of lean body mass. The safety profile is quite favorable with a small, but significant, incidence of raised intracranial pressure, scoliosis, muscle and joint discomfort, including slipped capital femoral epiphysis. The approval of rhGH therapy for short, non-GH-deficient children has validated the notion of GH sensitivity, which gives the opportunity to some children with significant short stature, but with normal stimulated GH test results, to benefit from rhGH therapy and perhaps attain an adult height within the normal range and appropriate for their mid-parental target height (genetic potential).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nielsen, J., & Wohlert, M. (1991) · Human Genetics · doi:10.1007/bf01213097 · Cited by 1,193
Ho, K. K. Y., & _, _. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0631 · Cited by 615
Growth hormone therapy of Turner's syndrome: beneficial effect on adult height
Rosenfeld, R. G., Attie, K. M., Frane, J., Brasel, A., Burstein, S., Cara, J. F., Chernausek, S., Gotlin, R. W., Kuntze, J., Lippe, B. M., et al. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70452-4 · Cited by 265
(2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2187 · Cited by 256
Quigley, C. A., Crowe, B. J., Anglin, D. G., & Chipman, J. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8477 · Cited by 159
Davenport, M. L., Crowe, B. J., Travers, S. H., Rubin, K., Ross, J. L., Fechner, P. Y., Gunther, D. F., Liu, C., Geffner, M. E., Thrailkill, K., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2874 · Cited by 147
Long-term safety of recombinant human growth hormone in Turner syndrome
Bolar, K., Hoffman, A. R., Maneatis, T., & Lippe, B. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1723 · Cited by 116
Cited by
Ross, J. L., Lee, P. A., Gut, R., & Germak, J. (2015) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2015-1 · Cited by 28
Blankenstein, O., Snajderova, M., Blair, J., Pournara, E., Pedersen, B. T., & Petit, I. O. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1055 · Cited by 19
Backeljauw, P., Blair, J. C., Ferran, J.-M., Kelepouris, N., Miller, B. S., Pietropoli, A., Polak, M., Sävendahl, L., Verlinde, F., & Rohrer, T. R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad159 · Cited by 12
Metadata
- Authors
- Richmond, E., & Rogol, A. D.
- Venue
- Endocrine Development
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 18
- Pages
- 92-108
- ISSN
- 1421-7082 (ISSN-L)
- 1662-2979
- OpenAlex
- W1775160221
- Cited by
- 103
- References
- 7
- FWCI
- 42.32
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Indications for Growth Hormone Therapy for Children and Adolescents. https://app.cochat.ai/papers/10.1159/000316130
- The paper
- Richmond, E., & Rogol, A. D. (2010). Current Indications for Growth Hormone Therapy for Children and Adolescents. Endocrine Development. https://doi.org/10.1159/000316130
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.